<DOC>
	<DOC>NCT00607750</DOC>
	<brief_summary>This study is a double-masked, randomized, placebo-controlled study of the safety and preliminary efficacy of ATG003 (topical mecamylamine) in patients receiving maintenance injections of either ranibizumab or bevacizumab. Study Hypothesis: Mecamylamine could be effective in the treatment of neovascular AMD.</brief_summary>
	<brief_title>Safety and Efficacy of ATG003 in Patients With AMD Receiving Anti-VEGF</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Mecamylamine</mesh_term>
	<criteria>&gt; 55 years of age clinical diagnosis of neovascular AMD confounding ocular condition</criteria>
	<gender>All</gender>
	<minimum_age>56 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Wet AMD, Comentis, ATG003, mecamylamine</keyword>
</DOC>